Successful nintedanib desensitization: Due to two cases.
作者信息
Tepetam Fatma Merve, Özden Şeyma, Duman Dildar
机构信息
Clinic of Immunology and Allergy, Süreyyapaşa Chest Diseases and Chest Surgery Training and Research Hospital, İstanbul, Türkiye.
Clinic of Chest Diseases, Süreyyapaşa Chest Diseases and Chest Surgery Training and Research Hospital, İstanbul, Türkiye.
出版信息
Tuberk Toraks. 2023 Mar;71(1):105-106. doi: 10.5578/tt.20239912.
Abstract
摘要
相似文献
1
Successful nintedanib desensitization: Due to two cases.成功的尼达尼布脱敏治疗：基于两例病例。
Tuberk Toraks. 2023 Mar;71(1):105-106. doi: 10.5578/tt.20239912.
2
Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update.尼达尼布治疗特发性肺纤维化的疗效和安全性：更新。
Drugs R D. 2018 Mar;18(1):19-25. doi: 10.1007/s40268-017-0221-9.
3
Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study.尼达尼布治疗特发性肺纤维化患者的细胞外基质代谢生物标志物（INMARK 研究）：一项随机、安慰剂对照研究。
Lancet Respir Med. 2019 Sep;7(9):771-779. doi: 10.1016/S2213-2600(19)30255-3. Epub 2019 Jul 17.
4
Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.尼达尼布治疗特发性肺纤维化患者的长期安全性和耐受性：开放标签扩展研究 INPULSIS-ON 的结果。
Lancet Respir Med. 2019 Jan;7(1):60-68. doi: 10.1016/S2213-2600(18)30339-4. Epub 2018 Sep 14.
5
Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report.吡非尼酮与尼达尼布联合治疗特发性肺纤维化成功：一例报告
Respiration. 2016;91(4):327-32. doi: 10.1159/000444690. Epub 2016 Apr 14.
6
Nintedanib for idiopathic pulmonary fibrosis in the Japanese population.尼达尼布用于日本人群特发性肺纤维化的治疗。
Respirology. 2017 May;22(4):630-631. doi: 10.1111/resp.13033. Epub 2017 Apr 3.
7
Nintedanib for idiopathic pulmonary fibrosis: An Asian perspective.
Respirology. 2016 Nov;21(8):1342-1343. doi: 10.1111/resp.12903. Epub 2016 Sep 20.
8
Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis.尼达尼布：用于特发性肺纤维化患者的评价。
Drugs. 2015 Jul;75(10):1131-40. doi: 10.1007/s40265-015-0418-6.
9
Nintedanib for the treatment of idiopathic pulmonary fibrosis.尼达尼布用于治疗特发性肺纤维化。
Expert Opin Pharmacother. 2018 Feb;19(2):167-175. doi: 10.1080/14656566.2018.1425681. Epub 2018 Jan 12.
10
Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension.尼达尼布治疗特发性肺纤维化患者的长期疗效：来自 TOMORROW 试验及其开放标签扩展研究的结果。
Thorax. 2018 Jun;73(6):581-583. doi: 10.1136/thoraxjnl-2016-209701. Epub 2017 Oct 9.
本文引用的文献
1
Pirfenidone: A novel hypothetical treatment for COVID-19.吡非尼酮：一种针对新型冠状病毒肺炎的新型假设性治疗方法。
Med Hypotheses. 2020 Nov;144:110005. doi: 10.1016/j.mehy.2020.110005. Epub 2020 Jun 17.
2
Nintedanib in advanced NSCLC: management of adverse events.尼达尼布治疗晚期非小细胞肺癌：不良事件的管理
Lung Cancer Manag. 2016 Apr;5(1):29-41. doi: 10.2217/lmt.15.33. Epub 2015 Nov 3.
3
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.尼达尼布治疗特发性肺纤维化的疗效和安全性。
N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18.
4
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).吲哚啉酮类作为三重血管激酶抑制剂的设计、合成与评估以及一种高度特异性的6-甲氧基羰基取代吲哚啉酮（BIBF 1120）的发现
J Med Chem. 2009 Jul 23;52(14):4466-80. doi: 10.1021/jm900431g.
5
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.BIBF 1120：具有持续受体阻断作用和良好抗肿瘤疗效的三联血管激酶抑制剂。
Cancer Res. 2008 Jun 15;68(12):4774-82. doi: 10.1158/0008-5472.CAN-07-6307.
Zotero 插件